Tyra Bioscience (TYRA)
NASDAQ:TYRA
Tyra-300 60Mg, Tyra-300 50Mg, Tyra-300 Dose Tbd
Low-Grade Nmibc, Fgfr Gene Amplification, Fgfr Gene Alterations, Fgfr3 Gene Alteration, Fgfr3 Gene Mutation, Fgfr3 Gene Fusions
Phase II
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Apr 25, 2025
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Tyra Bioscience (TYRA) have in its pipeline
TYRA is currently developing the following drugs: Tyra-300 60Mg, Tyra-300 50Mg, Tyra-300 Dose Tbd, Tyra-300 0.125 Mg/Kg, Tyra-300 0.25 Mg/Kg, Tyra-300 0.375 Mg/Kg, Tyra-300 0.50 Mg/Kg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.